Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
BRISTOL-MYERS SQUIBB U.S. PHARMACEUTICAL GROUP (TW)
ATC Code
J05AF02
Source
TFDA
AU:B2
J05AF02(WHO)
UK:POM(Prescription only)US:℞-only
9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3H-purin-6(9H)-one
69655-05-6Y
135398739
4833
DB00900Y
45864Y
K3GDH6OH08
D00296Y
CHEBI:490877Y
ChEMBL1460Y
000004
DTXSID6022927
Interactive image
O=C3/N=C\Nc1c3ncn1[C@@H]2O[C@@H](CC2)CO
InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1YKey:BXZVVICBKDXVGW-NKWVEPMBSA-NY
Didanosine, sold under the brand nameVidexamong others, is amedicationused to treatHIV/AIDS.It is used in combination with other medications as part ofhighly active antiretroviral therapy(HAART). It is of thereverse-transcriptase inhibitorclass.
Didanosine was first described in 1975 and approved for use in the United States in 1991.
⚠️ Warnings
• Caution should be exercised in patients with history of advanced HIV infection (AIDS), kidney, liver problems, gallstones, nerve problems, high blood cholesterol, any allergy, who are taking other medications, elderly, children especially less than 2 yeas old, during pregnancy and breastfeeding.
• Avoid alcohol consumption.
• It may cause severe side effects such as severe liver impairment, lactic acidosis in patients who are over weight, and in women. Those patients should consult with their doctor before taking this medication.
• Avoid sexual contact with your partner during the treatment to prevent the spread of HIV infection.
• Need to perform periodic eye exams.
• Monitor liver function, complete blood cell counts, and blood clotting while taking this medication.